

12 September 2025

ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine", or the "Company")

Grant of Options

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that on 11 September 2025, the Company granted a total of 300,000 options to subscribe for new common shares in the Company ("Options") to a key consultant.

The Options all have an exercise price of 15.50 pence, being the closing midmarket share price on 11 September 2025 (the "Approval Date"), the day on which the grant of Options was approved by the Board. The Options vest evenly over a period of three years, with 33.33% vesting on each of the three successive anniversaries of the Approval Date and can be exercised for a period of eight years from the Approval Date.

Following the grant of the Options, the Company has 18,863,334 options to subscribe for new common shares outstanding, which represents 3.64% per cent of the Company's current issued share capital.

Enquiries, please contact:
Ondine Biomedical Inc.

Carolyn Cross, CEO

www.ondinebio.com
+1 604 669 0555
or via Vane Percy & Roberts

Strand Hanson Limited (Nominated & Financial Adviser)

James Harris, Richard Johnson

+44 (0)20 7409 3494

Peel Hunt LLP (Broker & Joint Financial Adviser)

James Steel, Dr. Chris Golden

+44 (0)20 7418 8900

Vane Percy & Roberts (Media Contact)

Simon Vane Percy

+44 (0)77 1000 5910

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada and several other countries under the name Steriwave[®]. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

